SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The State of Innovation in Drug Development
1 references·10 citing·37 second hop
The State of Innovation in Drug Development (2008)The State of Innovation in Drug Developme…Can the pharmaceutical industry reduce attrition rates? (2004)Can the pharmaceutical indust…Reconceptualising innovation failure (2023)Reconceptualising innovation …Orphan Drugs and Their Impact on Pharmaceutical Development (2018)Orphan Drugs and Their Impact…Facilitating Radical Front‐End Innovation Through Targeted HRM Practices: A Case Study of Pharmaceutical and Biotech Companies (2017)Facilitating Radical Front‐En…Behavioral profiling as a translational approach in an animal model of posttraumatic stress disorder (2016)Behavioral profiling as a tra…Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs (2014)Medicines for the Mind: Polic…Caring for healthcare entrepreneurs — Towards successful entrepreneurial strategies for sustainable innovations in Dutch healthcare (2013)Caring for healthcare entrepr…An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011 (2013)An Improved Approach To Measu…Syndicate Innovation Venturing: Translating Academic Innovations into Commercial Successes (2012)Syndicate Innovation Venturin…The Biomarkers Consortium: Practice and Pitfalls of Open-Source Precompetitive Collaboration (2010)The Biomarkers Consortium: Pr…Translation of rare disease research into orphan drug development: disease matters (2009)Translation of rare disease r…The price of innovation: new estimates of drug development costs (2003)Clinical development success rates for investigational drugs (2014)Open innovation networks between academia and industry: an imperative for breakthrough therapies (2009)Patent data mining: A tool for accelerating HIV vaccine innovation (2011)Lessons from 60 years of pharmaceutical innovation (2009)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 (2010)Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders (2014)Public sector financial support for late stage discovery of new drugs in the United States: cohort study (2019)Missing Novelty in Drug Development (2021)Official Journal of the European Communities (1984)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences (2011)Cost of disorders of the brain in Europe 2010 (2011)Translating a rodent measure of negative bias into humans: the impact of induced anxiety and unmedicated mood and anxiety disorders (2019)The Iron Cage Revisited: Institutional Isomorphism and Collective Rationality in Organizational Fields (1983)Case Study Research: Design and Methods (1984)Case Study Research: Design and Methods (1991)Monitoring Viability and Sustainability in Healthcare Organizations (2018)Evaluating the effect of green technological innovations on organizational and environmental performance: A treble innovation approach (2023)Mapping sustainability practices in the healthcare sector: A systematic literature review and future research agenda (2023)The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies (2001)Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication (2005)Diagnostic and Statistical Manual of Mental Disorders (2013)Title: “Labels Matter: Is it stress or is it Trauma?” (2021)Building Theories from Case Study Research (1989)Qualitative Data Analysis: An Expanded Sourcebook (1994)Theory Building From Cases: Opportunities And Challenges (2007)The Roles of Knowledge Providers, Knowledge Recipients, and Knowledge Usage in Bridging Structural Holes (2018)HRM work and open innovation: evidence from a case study (2022)The Implications of Knowledge-Based HRM Practices on Open Innovations for SMEs in the Manufacturing Sector (2023)The productivity crisis in pharmaceutical R&D (2011)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Firm Resources and Sustained Competitive Advantage (1991)The Knowledge-Creating Company (1995)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Public sector innovation through nested experimental spaces: Reinventing the immigrant integration system (2025)
this work references cited by second hop

References

  • 2004Can the pharmaceutical industry reduce attrition rates?4,167 cited

Cited by

  • 2013An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011138 cited
  • 2016Behavioral profiling as a translational approach in an animal model of posttraumatic stress disorder87 cited
  • 2009Translation of rare disease research into orphan drug development: disease matters75 cited
  • 2014Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs75 cited
  • 2013Caring for healthcare entrepreneurs — Towards successful entrepreneurial strategies for sustainable innovations in Dutch healthcare65 cited
  • 2018Orphan Drugs and Their Impact on Pharmaceutical Development65 cited
  • 2023Reconceptualising innovation failure64 cited
  • 2010The Biomarkers Consortium: Practice and Pitfalls of Open-Source Precompetitive Collaboration51 cited
  • 2017Facilitating Radical Front‐End Innovation Through Targeted HRM Practices: A Case Study of Pharmaceutical and Biotech Companies33 cited
  • 2012Syndicate Innovation Venturing: Translating Academic Innovations into Commercial Successes9 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work